Improves glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg.
This medicine is generally administered once daily with the evening meal.
The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg.
Patients with no prior experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy:
When used as initial therapy in patients with no prior experience of antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily.
The dose should be adjusted gradually to reduce gastrointestinal adverse effects of metformin.
In patients receiving treatment with metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the dose of metformin previously taken or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate.
In patients switching to this medicine from combination therapy with dapagliflozin and metformin, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously taken. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate.
When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia.
The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from another glucose-lowering agent. Since this may cause changes in glycemic control, any change in treatment of patients with type 2 diabetes should be made under careful monitoring.
This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the feces as a soft, hydrated mass resembling a tablet.
Renal impairment
No dose adjustment is necessary in patients with mild renal impairment.
In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2, and without other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg.
Administration of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2.
If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months.
Elderly patients
Because metformin is excreted through the kidneys and renal function is more likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Use in Elderly Patients).
Improves glycemic control in adults with type 2 diabetes mellitus
Type 2 diabetes
abnormal blood sugar control
cardiovascular disease
cardiovascular risk factors
View approved original textHide original text
This medication is used to assist in blood sugar control in adult patients with type 2 diabetes by combining dapagliflozin and metformin. It is administered as an adjunct to dietary and exercise therapy for effective blood sugar management. Furthermore, in type 2 diabetes patients who have insufficient blood sugar control with additional cardiovascular disease or risk factors, the effects of dapagliflozin on the occurrence of cardiovascular events should be referenced from a specialist. Therefore, this medication aids in blood sugar control and improves cardiovascular health in patients with type 2 diabetes.
How to take
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg.
This medicine is generally administered once daily with the evening meal.
The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg.
Patients with no prior experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy:
When used as initial therapy in patients with no prior experience of antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily.
The dose should be adjusted gradually to reduce gastrointestinal adverse effects of metformin.
In patients receiving treatment with metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the dose of metformin previously taken or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate.
In patients switching to this medicine from combination therapy with dapagliflozin and metformin, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously taken. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate.
When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia.
The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from another glucose-lowering agent. Since this may cause changes in glycemic control, any change in treatment of patients with type 2 diabetes should be made under careful monitoring.
This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the feces as a soft, hydrated mass resembling a tablet.
Renal impairment
No dose adjustment is necessary in patients with mild renal impairment.
In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2, and without other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg.
Administration of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2.
If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months.
Elderly patients
Because metformin is excreted through the kidneys and renal function is more likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Use in Elderly Patients).
Precautions
This medication helps lower blood sugar. However, it should not be used in patients with poor kidney function or conditions such as dehydration, severe infections, or cardiovascular problems. Women who are pregnant or breastfeeding should also refrain from taking this medication. It can occasionally cause a severe condition called lactic acidosis, so any symptoms must be reported to a doctor immediately. There is a risk of hypoglycemia, so caution is required when used with insulin or other hypoglycemic agents. During treatment, urinary tract infections or genital infections may occur, and any related symptoms should be treated immediately. For patients at risk of decreased blood volume or hypotension, blood pressure and kidney function should be monitored frequently. Vitamin B12 levels may decrease, so blood tests may be necessary during long-term treatment. Excessive alcohol consumption can increase risks, so caution is necessary. This medication should be discontinued for a certain period before and after surgery or radiographic procedures, and it should be restarted only after confirming normal kidney function. Elderly patients commonly experience decreased kidney function, so dosing adjustment and regular kidney function tests may be needed. In case of overdose, immediate medical attention is required. This medication has not been established as safe and effective for children.
Side effects
Severe lactic acidosis
severe hypoglycemia
vulvovaginitis
balanitis
genital infection
urinary tract infection
fungal infection
hypoglycemia
reduced fluid volume
thirst
Show 85 moreCollapse
diabetic ketoacidosis
dizziness
constipation
dry mouth
lumbago
dysuria
polyuria
nocturia
vulvar pruritus
genital pruritus
elevated hematocrit
reduced renal creatinine clearance
dyslipidemia
increased serum creatinine
elevated blood urea
weight loss
ketoacidosis
urosepsis
pyelonephritis
acute kidney injury
renal dysfunction
rash
diarrhea
nausea
vomiting
reduced vitamin B12
Guillain-Barré syndrome
bacterial pneumonia
sialadenitis
tendinitis
chest pain
thermal burn
wrist fracture
gastrointestinal stromal tumor
malignant neoplasm of the lung
uterine leiomyoma
atrial fibrillation
acute cholecystitis
upper abdominal pain
dyspepsia
abdominal discomfort
abdominal pain
gastric ulcer
irritable bowel syndrome
salivary gland mass
dental pain
headache
facial paralysis
peripheral neuropathy
paresthesia
drowsiness
tremor
nasopharyngitis
pharyngitis
adenoviral conjunctivitis
shingles
pneumonia
rhinitis
increased alanine aminotransferase
increased blood glucose
arthralgia
myalgia
myofascial pain syndrome
osteoarthritis
osteochondrosis
limb pain
periartritis
tendinosis
trigger finger
weakness
fatigue
peripheral edema
edema
pain
vitamin D deficiency
hyperglycemia
urethral syndrome
cough
hyperventilation
skin abrasion
itching
palpitations
insomnia
type 2a hyperlipidemia
sensorineural hearing loss
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius to preserve its effectiveness.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.